Related Experiment Video
Updated: Oct 5, 2026

Evaluation of the Storage Stability of Extracellular Vesicles
Published on: May 22, 2019
Flavonoid glucuronides are substrates for human liver beta-glucuronidase
K A O'Leary1, A J Day, P W Needs
1Nutrition, Health and Consumer Sciences Division, Institute of Food Research, Norwich, UK.
Abstract:
Quercetin glucuronides are the main circulating metabolites of quercetin in humans. We hypothesise that the potential availability of the aglycone within tissues depends on the substrate specificity of the deconjugating enzyme beta-glucuronidase towards circulating flavonoid glucuronides. Human tissues (small intestine, liver and neutrophils) exhibited beta-glucuronidase against quercetin glucuronides. The various quercetin glucuronides were deconjugated at similar rates, but liver cell-free extracts were the most efficient and the activity was completely inhibited by saccharo-1,4-lactone (a beta-glucuronidase inhibitor). Furthermore, pure recombinant human beta-glucuronidase hydrolysed various flavonoid glucuronides, with a 20-fold variation in catalytic efficiency (k(cat)/K(m)=1.3x10(3) M(-1) s(-1) for equol-7-O-glucuronide and 26x10(3) M(-1) s(-1) for kaempferol-3-O-glucuronide). Similar catalytic efficiencies were obtained for quercetin O-glucuronides substituted at different positions. These results show that flavonoid glucuronides can be deconjugated by microsomal beta-glucuronidase from various human cells.
More Related Videos
Related Concept Videos
Phase II Reactions: Glucuronidation
Drug Metabolism: Phase II Reactions
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Role of Transporters

